Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease c syndrome
Comorbidity C0282193|iron overload
Sentences 23
PubMedID- 26576280 iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy.
PubMedID- 25764148 Deferasirox (dfx) is an orally administered iron chelator approved for use in patients with transfusion-dependent iron overload due to myelodysplastic syndromes (mds).
PubMedID- 21069694 Deferasirox for managing iron overload in people with myelodysplastic syndrome.
PubMedID- 21822196 iron overload in patients with transfusion dependent myelodisplastic syndrome.
PubMedID- 25672910 Certain characteristics of metabolic syndrome are mainly attributed to iron overload (20).
PubMedID- 23628060 [current understanding of iron overload hazard in patients with myelodysplastic syndrome].
PubMedID- 25516455 Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
PubMedID- 19903678 Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a gitmo study.
PubMedID- 19719471 Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
PubMedID- 25743685 Overall, about 760 myelodysplastic syndrome (mds) patients with iron overload receiving deferasirox were included in six different studies, and an increase in hemoglobin level was reported to range from 6 to 44.5%, an increase in platelet count from 13 to 61%, and in neutrophil count from 3 to 76%.
PubMedID- 25348770 Objectives: to evaluate the effectiveness and safety of oral deferasirox for managing iron overload in people with myelodysplastic syndrome (mds).
PubMedID- 26453076 Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents.
PubMedID- 26224043 Background: hepatic iron overload is common in patients with myelodysplastic syndromes undergoing hematopoietic cell transplantation (hct) and may predispose to peri- and post-hct toxicity.
PubMedID- 20332502 iron overload in myelodysplastic syndromes.
PubMedID- 23937987 A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
PubMedID- 22338168 [pay great attention to the diagnosis and treatment of iron overload in myelodysplastic syndromes].
PubMedID- 23766520 Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes.
PubMedID- 22924125 Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial.
PubMedID- 20125080 iron overload in myelodysplastic syndromes: diagnosis and management.
PubMedID- 22890139 Two patients were undergoing phlebotomy and had no iron overload, 1 with metabolic syndrome and no phlebotomy had mild iron overload, and 2 patients had severe iron overload despite phlebotomy.
PubMedID- 22829233 Clearly elevated cardiac r2(*) was found in two myelodysplastic syndrome (mds) patients with severe liver iron overload.
PubMedID- 24598841 Dysregulation of hepcidin, a key iron regulating hormone, is important in the pathogenesis of iron overload in patients with myelodysplatic syndrome (mds).
PubMedID- 23086508 Transfusion therapy in the treatment of patients with blood disorders such as β-thalassemia major, sickle cell disease (scd), and myelodysplastic syndromes (mds) rapidly leads to iron overload and subsequent tissue and organ damage unless effective chelation therapy is used to control tissue iron levels [9, 10].

Page: 1